Jonathan Moreira

Jonathan Moreira

Hematology | Oncology
675 N Saint Clair St Ste 100 Fl 21
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

State of oral innate immunity and salivary microbiome with allogeneic hematopoietic stem cell transplant.

State of oral innate immunity and salivary microbiome with allogeneic hematopoietic stem cell transplant.

Journal: Microbiology spectrum
Published: August 10, 2026

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.

Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Journal: Cancers
Published: May 28, 2025

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Journal: Blood advances
Published: May 09, 2025

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Journal: Blood advances
Published: April 24, 2025

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.

Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.

Journal: Blood cancer journal
Published: September 03, 2024

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.

Journal: Blood advances
Published: January 04, 2024

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.

Journal: Blood advances
Published: November 13, 2023

Evaluating Socioeconomic, Racial, and Ethnic Disparities in Survival Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplants.

Evaluating Socioeconomic, Racial, and Ethnic Disparities in Survival Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplants.

Journal: Journal of racial and ethnic health disparities
Published: February 21, 2023

NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.

NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 15, 2023

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.

Journal: Blood advances
Published: January 17, 2023

Stem Cell Transplant Experiences Among Hispanic/Latinx Patients: A Qualitative Analysis.

Stem Cell Transplant Experiences Among Hispanic/Latinx Patients: A Qualitative Analysis.

Journal: International journal of behavioral medicine
Published: September 14, 2022
Showing 1-12 of 20

Last Updated: 09/26/2026